CCSG funds for Protocol Specific Research Support (PSRS) are used for development of NYUCI investigator initiated early phase protocols. The NYUCI places a high priority on such studies since they represent one of the most promising benefits of the NCI Cancer Centers Program. Approximately 23% of NYUCI therapeutic trials are Investigator-Initiated Trials. Accrual to investigator-initiated studies at NYUCI has increased by almost 10% over the last funding period and this category now accounts for 68.6% of all therapeutic accruals. Protocols considered for PSRS funds have to meet the following requirements: 1) Designation of high priority by a NYUCI Disease Management Group and/or CCSG Scientific Research Program; 2) Approval and high merit score by the Protocol Review &Monitoring Committee (PRMC); 3) Clearance provided by the Clinical Trials Office that all other institutional requirements and investigator's conduct of research are met;and 4) Recommendation by the PRMC, Cancer Institute Director and CCIC for funding. The CCIC, in conjunction with the PSRS Chair, review all relevant approvals, scores, and the financial assessment of the trial to make the determination about PSRS funding.

Public Health Relevance

Early phase clinical trials are an essential (and often the last) step in demonstrating that scientific advances originating in the laboratory are applicable to patients. PSRS provides mentorship and other resources for a team of investigators to achieve these goals.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-34
Application #
8765187
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
34
Fiscal Year
2014
Total Cost
$7,505
Indirect Cost
$3,077
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Saint Fleur-Lominy, Shella; Maus, Mate; Vaeth, Martin et al. (2018) STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 24:3045-3060.e5
Puranik, Amrutesh S; Leaf, Irina A; Jensen, Mark A et al. (2018) Kidney-resident macrophages promote a proangiogenic environment in the normal and chronically ischemic mouse kidney. Sci Rep 8:13948
Cui, Xin; Morales, Renee-Tyler Tan; Qian, Weiyi et al. (2018) Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. Biomaterials 161:164-178
Weng, Mao-Wen; Lee, Hyun-Wook; Park, Sung-Hyun et al. (2018) Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. Proc Natl Acad Sci U S A 115:E6152-E6161
Burgess, Hannah M; Pourchet, Aldo; Hajdu, Cristina H et al. (2018) Targeting Poxvirus Decapping Enzymes and mRNA Decay to Generate an Effective Oncolytic Virus. Mol Ther Oncolytics 8:71-81
Wong, Serre-Yu; Coffre, Maryaline; Ramanan, Deepshika et al. (2018) B Cell Defects Observed in Nod2 Knockout Mice Are a Consequence of a Dock2 Mutation Frequently Found in Inbred Strains. J Immunol 201:1442-1451
Handler, Jesse; Cullis, Jane; Avanzi, Antonina et al. (2018) Pre-neoplastic pancreas cells enter a partially mesenchymal state following transient TGF-? exposure. Oncogene 37:4334-4342
Diamond, Julie M; Vanpouille-Box, Claire; Spada, Sheila et al. (2018) Exosomes Shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs. Cancer Immunol Res 6:910-920
Fan, Xiaozhou; Peters, Brandilyn A; Jacobs, Eric J et al. (2018) Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
Chen, Danqi; Fang, Lei; Mei, Shenglin et al. (2018) Erratum: ""Regulation of Chromatin Assembly and Cell Transformation by Formaldehyde Exposure in Human Cells"". Environ Health Perspect 126:019001

Showing the most recent 10 out of 1170 publications